BBV154 Intranasal Vaccine

BIOLOGICAL2 trials

Sponsors

Bharat Biotech International Limited

Conditions

COVID-19 Respiratory InfectionCorona Virus Infection

Phase 2

BBV152/BBV154 Heterologus Prime-Boost Study

CompletedNCT05639998

Bharat Biotech International LimitedCorona Virus Infection

Start: 2021-09-01End: 2022-07-31Updated: 2022-12-07

Phase 3

Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose

CompletedNCT05567471

Bharat Biotech International LimitedCOVID-19 Respiratory Infection

Start: 2022-02-26End: 2022-09-28Updated: 2022-10-05

Related Papers

Effect of heterologous intranasal iNCOVACC<sup>®</sup> vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.

2025-04-231 citations

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin<sup>®</sup>).

2023-08-1856 citations